Today: 22 March 2026
Subscribe
Browse Category

NASDAQ:BNKK 20 November 2025

Bonk, Inc. (BNKK) Stock Jumps on Q3 2025 Earnings: Debt-Free Balance Sheet and 1,200% Beverage Revenue Surge

Bonk, Inc. (BNKK) Stock Jumps on Q3 2025 Earnings: Debt-Free Balance Sheet and 1,200% Beverage Revenue Surge

Bonk, Inc. reported Q3 2025 beverage revenue of $1.51 million, up over 1,200% year over year, and posted its first-ever gross profit in the segment. The company ended the quarter debt-free with about $9 million in cash. Shares surged Thursday as investors reacted to the results. Net loss remained large, mainly due to $17 million in one-time non-cash charges.
20 November 2025
··

Stock Market Today

  • CRISPR Therapeutics Stock Dips Amid Biotech Risks Despite Strong DCF Upside
    March 22, 2026, 2:39 AM EDT. CRISPR Therapeutics (CRSP) shares have fallen 14% year to date, contrasting with a 12.2% gain over the past year. The stock trades around $46.24, reflecting a 75.6% discount to its intrinsic value based on a Discounted Cash Flow (DCF) model projecting positive free cash flow by 2030. Despite short-term declines driven by biotech sector volatility and regulatory concerns, long-term growth potential linked to its gene-editing pipeline keeps investor interest. The company shows a $345.4 million free cash flow loss currently, moving to forecasted positive cash generation. Valuation metrics like price-to-book provide additional context amid earnings volatility. Market watchers may consider CRISPR's current weakness an opportunity, though risks remain given sector dynamics and cash flow uncertainty.
Go toTop